Antibodies News and Research

RSS

Two-dose ChAdOx1 vaccine protection wanes after three months

New research reported in the journal The Lancet examines the temporal association between the two-dose ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccination regimen and the risk of severe outcomes from COVID-19 in Scotland vs. Brazil, where the Delta variant of SARS-CoV-2 was dominant and rare, respectively.

21 Dec 2021

Broad neutralization of SARS-CoV-2 spike protein by an unconventional antibody fragment

A new preprint research paper posted to the bioRxiv* server examines the nature and effects of the spike mutations and identifies a vulnerable point that could help develop broad-spectrum protection against circulating variants.

21 Dec 2021

National U.S trial confirms effectiveness of mRNA COVID-19 vaccines

In a recent study, published in the Annals of Internal Medicine, scientists conducted a target trial emulation study and documented that among the elderly in the U.S. (with significant comorbidities), the efficacy of messenger RNA (mRNA) vaccines was much lower in terms of preventing infection, than previously reported. However, the effectiveness against death was found to be high.

21 Dec 2021

Early administration of SARS-CoV-2 convalescent plasma reduces outpatient hospitalizations

The results of a nationwide, multicenter clinical trial led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health provides solid evidence for the use of plasma from convalescent patients — those who have recovered from the disease and whose blood contains antibodies against SARS-CoV-2, the virus that causes COVID-19 — as an early treatment.

21 Dec 2021

Molecular mechanism of SARS-Cov-2-induced thrombosis

Researchers demonstrate that the exposure of platelets to the SARS-CoV-2 spike protein promotes their activation and adhesion.

21 Dec 2021

Severe COVID-19 found to be associated with disrupted intestinal Peyer’s patches

A new study demonstrates significantly altered structure and cellularity of Peyer’s patches in deceased COVID-19 patients.

21 Dec 2021

Identifying a recurring pattern in broadly neutralizing antibodies that can target an epitope on SARS-CoV-2

Interesting research decrypts a recurring sequence in antibodies against severe acute respiratory syndrome 2 (SARS-CoV-2) and identifies it to be a board neutralizing antibody that targets a conserved epitope on the SARS-CoV-2 receptor-binding domain (RBD) of the spike protein.

21 Dec 2021

Pandemic poses short- and long-term risks to babies, especially boys

The pandemic has created a hostile environment for pregnant people and their babies. Stress levels among expectant mothers have soared. Pregnant women with covid are five times as likely as uninfected pregnant people to require intensive care and 22 times as likely to die. Infected moms are four times as likely to have a stillborn child.

21 Dec 2021

Booster shots improve CD8+ T cell response to SARS-CoV-2 in animal model

In a new study, published on the bioRxiv* preprint server, scientists showed in a mice model that three doses of the same synthetic peptide vaccine, eliciting an exclusive CD8+ T cell response against one SARS-CoV-2 Spike epitope, protected against lethal SARS-CoV-2 infection, in the absence of neutralizing antibodies. Researchers also showed that the third dose resulted in superior generation of effector-memory T cells in the circulation and tissue-resident memory T (TRM) cells.

20 Dec 2021

An Omicron wave predicted for England from December 2021 to April 2022

A study, published on the medRxiv* preprint server, focuses on the interaction between Omicron variants and public health interventions in England that promote immunity.

20 Dec 2021

New oral pill for COVID-19 home treatment

As cases and hospitalizations continue to rise in many countries, new treatments are being sought to arrest the progression of the disease, preventing severe illness and death or disability. One such is the small molecule molnupiravir, the focus of a new research paper.

20 Dec 2021

New study suggests most monoclonal antibody treatments are ineffective against Omicron SARS-CoV-2 variant

The arrival of the Omicron (B.1.1.529) variant has brought into question the effectiveness of current COVID-19 treatments in preventing infection and death. New research published in the preprint bioRxiv* server suggests the efficacy of most monoclonal antibody treatments are ineffective against Omicron.

20 Dec 2021

New Omicron variant may be better at evading vaccine-induced antibodies, research shows

The Omicron variant of SARS-CoV-2 may be significantly better than previous variants at evading vaccine-induced antibodies, according to new research from Cambridge - but preliminary evidence suggests it is less likely to cause severe COVID-19 illness in the lungs.

20 Dec 2021

Antibodies News and Research

Two-dose ChAdOx1 vaccine protection wanes after three months

Broad neutralization of SARS-CoV-2 spike protein by an unconventional antibody fragment

National U.S trial confirms effectiveness of mRNA COVID-19 vaccines

Early administration of SARS-CoV-2 convalescent plasma reduces outpatient hospitalizations

Molecular mechanism of SARS-Cov-2-induced thrombosis

Severe COVID-19 found to be associated with disrupted intestinal Peyer’s patches

Identifying a recurring pattern in broadly neutralizing antibodies that can target an epitope on SARS-CoV-2

Pandemic poses short- and long-term risks to babies, especially boys

Booster shots improve CD8+ T cell response to SARS-CoV-2 in animal model

An Omicron wave predicted for England from December 2021 to April 2022

New oral pill for COVID-19 home treatment

New study suggests most monoclonal antibody treatments are ineffective against Omicron SARS-CoV-2 variant

New Omicron variant may be better at evading vaccine-induced antibodies, research shows

Omicron variant of SARS-CoV-2 exhibits striking antibody evasion

Reduced antibody-mediated neutralization by the SARS-CoV-2 Omicron variant

Researchers predict 200% increase in European coronavirus cases as Omicron spreads

Computational analysis of the effect of SARS-CoV-2 Omicron variant spike protein mutations

A test to identify antibody effectiveness against COVID-19 variants

Anti-SARS-CoV-2 antibody infusion shown to demonstrate robust immune response following COVID-19 vaccination

Humanized mice reveals why few COVID-19 cases are more severe than others

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo